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To the Editor: Although the study by Chertow et al
has shown that in hemodialysis patients, sevelamer com-
pared to calcium-based phosphate binders is less likely
to cause hypercalcemia and arterial calcifications, we do
not think that in the patients of this study sevelamer
should replace CaCO3. Indeed, their mild hyperparathy-
roidism could have been corrected by just higher doses
Fig. 1. Progression of calcium score as measured by electron beam of CaCO3 alone without aluminum hydroxide [Al (OH)3]tomography in coronaric artery in people with different lipid status.
or calcitriol. In fact, a high dose of CaCO3, without theFaster progression was associated with high lipids in all studies (at least
10 months of follow-up). Callister (N Engl J Med 339:1972, 1998, cited by co-administration of calcitrol, offers the distinct advan-
Chertow, Burke, and Raggi) reported a 52% rate of progression in pa- tage of maintaining lower serum-phosphate concentra-tients with coronary artery disease left untreated versus 25% in patients
treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re- tion without higher serum calcium [1]. This is probably
ductase inhibitors and low-density lipoprotein (LDL) cholesterol. Bu- due to the fact that calcitriol increases intestinal absorp-
doff (Am J Cardiol 86:8, 2000) reported 39% versus 15% in the presence
tion of phosphate whereas CaCO3 decreases it.of statin therapy in asymptomatic subjects. Pohle (Circulation 104:1927,
2001) reported 39% in patients with aortic valve calcification versus 16% Therefore, to clinically justify the preferential use of
in those with low LDL. Tamashiro et al (Am J Kidney Dis 38:64–69, “sevelamer plus calcitriol” over that of CaCO3, the lower2001) reported a faster rate of progression in dialysis patients with high
risk of arterial calcification should have been demon-trygliceride and low high-density lipoprotein (HDL) cholesterol (the
absolute number,432 458 versus7.5 31 are changed in percent- strated against higher doses of CaCO3 without calcitriolage in this figure to obtain an homogeneous picture)
while actually obtaining in both groups the same “tar-
geted” ranges for serum concentrations of parathyroid
hormone, calcium, and phosphate. The issue is indeed to
vascular calcification is an active process, did hyper- know whether despite comparable serum chemistry, the
calcemic patients also lack any progression? higher oral doses of calcium are actually increasing
Finally, since calcium and sevelamer patients should
the arterial calcium load more than calcitriol. However,
have different acid-base status, was there a relationship
the negative direct bone mineralization effect of calcitriolbetween serum bicarbonate and calcification progres-
shown in vitamin D-receptor knockout mice [2] does notsion? Evidence shows that, to prevent vasculopathy, it is
support this possibility.important to avoid hypercalcemia (not normal calcemia)
The second issue is to know whether prevention ofby perhaps lowering the acceptable high end calcium
arterial calcification will improve cardiovascular risk in-range in order to reduce the risk of unwanted escape in
dependently of the improvement of uremic dyslipidemia,addition to hyperphosphoremia, dyslipemia, alkalosis,
which promotes atherosclerosis and therefore intimaland other medial manifestations.
calcification. Indeed, the control of dyslipidemia with
Caterina Canavese, Daniela Bergamo, Hamido Dib, statin decreases cardiovascular morbid mortality in high-
Francesca Bermond, and Manuel Burdese risk patients [3] and is much cheaper than sevelamer asTorino, Italy
a cholesterol-lowering drug.
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sion of cardiovascular calcification, including the type of
calcium-containing binder (calcium acetate is twice as effec-
tive as calcium carbonate yet contains half the amount ofTo the Editor: In their unblinded study of vascular
elemental calcium), dialysate calcium, vitamin D dose,calcification in dialysis patients, Chertow et al combine
and lipid levels. Did sevelamer-treated patients receive
results from patients receiving calcium acetate with those
a nighttime calcium supplement or increased dialysate
from patients receiving calcium carbonate. Use of these calcium to prevent hypocalcemia? Were there differences
calcium salts interchangeably in studies is not appro- in progression of calcification between calcium acetate-
priate since calcium acetate is a more potent phosphate and calcium carbonate-treated patients? Since vitamin D
binder with less calcium absorption [1]. This can be seen increases calcium absorption and hypercalcemia risk, and
in the study of Chertow et al by the differences in re- may itself predispose to cardiovascular calcification [2],
quired doses. If the hypothesis concerning the relation- Chertow et al should have controlled for vitamin D use.
ship of calcification to oral calcium advanced by the In the calcium-treated patients, low-density lipoprotein
authors is correct, it would be very useful to see the (LDL) cholesterol should have been controlled to an equiv-
study results analyzed for each salt separately in order alent level with 3-hydroxy-3-methylglutaryl coenzyme A
to test for dose response effects. This is particularly im- (HMG-CoA) reductase inhibitors. Given failure to ade-
portant because the average daily dose of calcium acetate quately control other important variables, this study by
required by patients in this study was nearly equivalent Chertow et al clearly does not establish a causal relation-
to the USRDA for calcium. ship between cardiovascular calcification and possible
It is likely that the sevelamer patients received supple- calcium loading from calcium-containing binders. We,
therefore, believe that this study by Chertow et al doesmental calcium (as shown by the absence of change in se-
not justify preferential use of the considerably more ex-rum calcium levels over the course of the year and that
pensive phosphate binder sevelamer hydrochloride. Fi-some also experienced hypercalcemia). Traditionally, in
nally, could the metabolic acidosis in this and other stud-studies of sevelamer, 1 gram of supplemental calcium is
ies be explained by an acid load provided by sevelameroften given to prevent hypocalcemia [2]. This dose is
hydrochloride [3].nearly equivalent to the calcium dose utilized by Cher-
tow et al in the calcium treatment arm. Clearly, there was
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